Anticoagulation therapy in the antiphospholipid syndrome: Recent advances

Current Opinion in Pulmonary Medicine

Volumn 11, Issue 5, 2005, Pages 368-372

  Ng, Heng Joo ^a   Crowther, Mark A ^b,c  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b ST JOSEPH S HOSPITAL   (Canada)

^c HEART AND STROKE FOUNDATION OF CANADA   (Canada)

Author keywords

Antiphospholipid antibodies; Oral anticoagulants; Pregnancy; Pregnancy loss; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; CARDIOLIPIN ANTIBODY; PHOSPHOLIPID ANTIBODY; WARFARIN;

ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; BLEEDING; DISEASE CLASSIFICATION; DRUG EFFECT; GRAFT FAILURE; HUMAN; KIDNEY ALLOGRAFT; LONG TERM CARE; PREGNANCY COMPLICATION; PROGNOSIS; RECURRENT DISEASE; REVIEW; THROMBOEMBOLISM; THROMBOSIS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 24744459638     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/01.mcp.0000174229.24854.2e     Document Type: Review

References (35)

1. Wilson WA, Gharavi AE, Piette JC. International classification criteria for antiphospholipid syndrome: synopsis of a post-conference workshop held at the Ninth International (Tours) aPL Symposium. Lupus 2001; 10:457-460.
2. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002; 346:752-763.
3. Schulman S, Svenungsson E, Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. Am J Med 1998; 104:332-338.
4. Rosove MH, Brewer PM. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med 1992; 117:303-308.
5. Derksen RH, de Groot PG, Kater L, Nieuwenhuis HK. Patients with antiphospholipid antibodies and venous thrombosis should receive long-term anticoagulant treatment. Ann Rheum Dis 1993; 52:689-692.
6. Khamashta MA, Cuadrado MJ, Mujic F, et al. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995; 332:993-997.
7. Crowther MA, Wisloff F. Evidence based treatment for the antiphospholipid antibody syndrome II: optimal anticoagulant therapy for thrombosis. Thromb Res 2005; 115:3-8.
8. Brey RL, Stallworth CL, McGlasson DL, et al. Antiphospholipid antibodies and stroke in young women. Stroke 2002; 33:2396-2401. [comment]
9. Brey RL, Abbott RD, Curb JD, et al. beta(2)-Glycoprotein 1-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction: the Honolulu Heart Program. Stroke 2001; 32:1701-1706.
10. Levine SR, Brey RL, Tilley BC, et al. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA 2004; 291(5):576-584. In this prospective cohort study within the Warfarin vs Aspirin Recurrent Stroke Study, 1 770 patients were tested for APLa and monitored for 2 years for recurrent thrombo-occlusive events. The presence of APLa did not predict either an increase risk for subsequent vascular occlusive events or a differential response to warfarin or aspirin therapy.
11. Tanne D, D'Olhaberriague L, Schultz LR, et al. Anticardiolipin antibodies and their associations with cerebrovascular risk factors. Neurology 1999; 52:1368-1373.
12. Sletnes KE, Smith P, Abdelnoor M, et al. Antiphospholipid antibodies after myocardial infarction and their relation to mortality, reinfarction, and non-haemorrhagic stroke. Lancet 1992; 339:451-453. (see comments).
13. Wagenknecht DR, Becker DG, LeFor WM, McIntyre JA. Antiphospholipid antibodies are a risk factor for early renal allograft failure. Transplantation 1999; 68:241-246.
14. Vaidya S, Wang CC, Gugliuzza C, Fish JC. Relative risk of post-transplant renal thrombosis in patients with antiphospholipid antibodies. Clin Transplant 1998; 12:439-444.
15. Forman JP, Lin J, Pascual M, et al. Significance of anticardiolipin antibodies on short and long term allograft survival and function following kidney transplantation. Am J Transplant 2004; 4(11):1786-1791. A cohort of 337 patients undergoing renal transplantation were tested for aCL and monitored during the end of the study period. Although there was no difference in outcome (allograft loss or worsening of renal function) between antibody-positive and -negative patients, subgroups of patients with high titers or APS clearly benefited from anticoagulation.
16. Crowther MA, Ginsberg JS, Gent M, et al. A randomized trial of two intensities of warfarin (international normalized ratio of 2.0 to 3.0 versus 3.1 to 4.0) for the prevention of recurrent thrombosis in patients with antiphospholipid antibodies. N Engl J Med 2003; 349:1133-1138.
17. Finazzi G, Marchioli R, Barbui T, et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost 2005; 3:848-853.
18. Brunner HI, Chan WS, Ginsberg JS, Feldman BM. Longterm anticoagulation is preferable for patients with antiphospholipid antibody syndrome: result of a decision analysis. J Rheumatol 2002; 29:490-501.
19. Khamashta MA. Management of thrombosis and pregnancy loss in the antiphospholipid syndrome. Lupus 1998; 7(Suppl 2):S162-S165.
20. Buller HR, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126:4013-4285. This latest evidence-based guideline provides recommendation for the intensity and duration of warfarin therapy for APS patients.
21. De Wolf F, Carreras LO, Moerman P, Renaer M, et al. Decidual vasculopathy and extensive placental infarction in a patient with repeated thromboembolic accidents, recurrent fetal loss, and a lupus anticoagulant. Am J Obstet Gynecol 1982; 142:829-834.
22. di Somone N, Meroni PL, de Papa N, et al. Antiphospholipid antibodies affect trophoblast gonadotropin secretion and invasiveness by binding directly and through adhered beta2-glycoprotein I. Arthritis Rheum 2000; 43:140-150.
23. Holers VM, Girardi G, Mo L, et al. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med 2002; 195:211-220.
24. Girardi G, Berman J, Redecha P, et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest 2003; 112:1644-1654.
25. Girardi G, Redecha P, Salmon JE. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med 2004; 10(11):1222-1226. In this study based on a murine model, prevention of pregnancy loss by heparin was postulated to be due to inhibition of complement activation rather than to its anticoagulant effect.
26. Empson M, Lassere M, Craig JC, Scott JR. Recurrent pregnancy loss with antiphospholipid antibody: a systematic review of therapeutic trials. Obstet Gynecol 2002; 99:135-144.
27. Wisloff F, Crowther M. Evidence-based treatment of the antiphospholipid syndrome: I. Pregnancy failure. Thromb Res 2004; 114:75-81.
28. Laskin CA, Bombardier C, Hannah ME, et al. Prednisone and aspirin in women with autoantibodies and unexplained recurrent fetal loss. N Engl J Med 1997; 337:148-153.
29. Triolo G, Ferrante A, Ciccia F, et al. Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulin in the treatment of recurrent fetal loss associated with antiphospholipid antibodies. Arthritis Rheum 2003; 48(3):728-731.
30. Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ 1997; 314:253-257.
31. Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low- dose aspirin alone. Am J Obstet Gynecol 1996; 174:1584-1589.
32. Pettila V, Kaaja R, Leinonen P, et al. Thromboprophylaxis with low molecular weight heparin (dalteparin) in pregnancy. Thromb Res 1999; 96:275-282.
33. Noble LS, Kutteh WH, Lashey N, et al. Antiphospholipid antibodies associated with recurrent pregnancy loss: prospective, multicenter, controlled pilot study comparing treatment with low-molecular-weight heparin versus unfractionated heparin. Fertil Steril 2005; 83:684-690. The use of LMWH with aspirin seems to be as safe as UFH with aspirin, according to this pilot study.
34. Ruffatti A, Favaro M, Tonello M, et al. Efficacy and safety of nadroparin in the treatment of pregnant women with antiphospholipid syndrome: a prospective cohort study. Lupus 2005; 14(2):120-128. More than 90% live births were reported in this study, which used twice-daily nadroparin in the treatment of patients with APS.
35. Farquharson RG, Quenby S, Greaves M. Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstet Gynecol 2002; 100:408-413.